Frontline Treatment Options for Hodgkin's Lymphoma

Video

Frontline Treatment Options for Hodgkin's Lymphoma

A 32-Year-Old Man with Stage IV Hodgkin's Lymphoma

  • History & Physical:
    • A 32-year-old man presented to his PCP in January 2017 complaining of abdominal pain, pruritus, fevers of over 101⁰ F, and weight loss
  • Imaging
    • PET scan showed avid mediastinal mass
  • Labs
    • HgB 12.2 g/dL
    • WBC 7,500 mm2
    • ALC 3,200 mm2
    • Albumin 3.9 mg/dL
    • ANC 4,200/mm3
    • Liver and renal function tests WNL
  • Biopsy confirmed mixed cellularity classical Hodgkin’s lymphoma (HL)
  • Normal lung and cardiac function
  • Final Staging: Stage IVB, cHL, IPS score 2
  • ECOG PS 2
  • He received 2 cycles of ABVD. PET/CT restaging showed Deauville (1-). He received 4 additional cycles of AVD
  • He achieved a CR
  • 2 years after completion of therapy, the patient complained of a persistent cough and fatigue
  • PET/CT showed bilateral mediastinal masses
  • Biopsy confirmed cHL
Related Videos
Yi-Bin Chen, MD, an expert on GVHD
Yi-Bin Chen, MD, an expert on GVHD
Video 6 - "Quality of Life + Clinical Monitoring Outside the Transplant Center"
Video 5 - "Second-Line Medications and Toxicities in GVHD"
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Related Content
Positive Topline Data With Nana-val in EBV+ PTCL

Positive Topline Data With Nana-val in EBV+ PTCL

April 16th 2024
Article

Combination therapy with nanatinostat and valganciclovir led to promising response rates among patients with Epstein-Barr Virus-positive peripheral T-cell lymphoma.

Read More

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

July 15th 2022
Podcast

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

Listen

IND Application Submitted to FDA for SynKIR-310 Trial in R/R B-NHL

IND Application Submitted to FDA for SynKIR-310 Trial in R/R B-NHL

April 3rd 2024
Article

An investigational new drug application for SynKIR-310's phase 1 trial targeting relapsed/refractory B-cell non-Hodgkin lymphomas was submitted to the FDA.

Read More

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

June 15th 2022
Podcast

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Listen

PROSPECT Study of Tirabrutinib in R/R PCNSL Completes Part A Enrollment

PROSPECT Study of Tirabrutinib in R/R PCNSL Completes Part A Enrollment

March 27th 2024
Article

The first arm of the phase 2 PROSPECT study evaluating tirabrutinib for the treatment of relapsed/refractory primary central nervous system lymphoma has finished enrolling patients.

Read More

FDA Denies Approval of Odronextamab in DLBCL and Follicular Lymphoma

FDA Denies Approval of Odronextamab in DLBCL and Follicular Lymphoma

March 25th 2024
Article

The FDA issued a pair of complete response letters for the biologics license application for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

Read More